obinutuzumab
Obinutuzumab is a drug used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Obinutuzumab is being actively studied in 98 studies and prior, has been studied in 40.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Hoffmann-La Roche | Hospital Universitari Vall d'Hebron; Servicio de Hematologia | Jonathon Cohen |
| Genentech, Inc. | M D Anderson Cancer Center | Joseph Tuscano |
| M.D. Anderson Cancer Center | Samsung Medical Center | Matthew S. Davids, MD |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Bendamustine
- Obinutuzumab
- Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
2021-04-05
Apr 5, 2021M
Not yet recruiting
- Primary Focal Segmental Glomerulosclerosis
- Obinutuzumab
- Rochester, MinnesotaMayo Clinic in Rochester
2021-10-15
Oct 15, 2021N
Active, not recruiting
- Leukemia
- +3 more
- rhIL-15
- obinutuzumab
- Bethesda, MarylandNational Institutes of Health Clinical Center
2021-12-01
Dec 1, 2021K
Suspended
- Primary CNS Lymphoma
- Venetoclax
- Obinutuzumab
- Stuttgart, Baden-Württemberg, GermanyKlinikum Stuttgart
2021-09-15
Sep 15, 2021A
Not yet recruiting
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
- (no location specified)
2021-11-23
Nov 23, 2021I
Not yet recruiting
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
2021-10-20
Oct 20, 2021F
Active, not recruiting
- Waldenstrom Macroglobulinemia
- Obinutuzumab
- Idelalisib
- Tours, FranceProject manager
2021-06-28
Jun 28, 2021U
Recruiting
- Follicular Lymphoma
- Venetoclax
- +2 more
- Chicago, IllinoisUniversity of Chicago Medical Center
2021-11-12
Nov 12, 2021M
Not yet recruiting
- Membranous Nephropathy
- Obinutuzumab
- Bergamo, BG, Italy
- +1 more
2021-09-09
Sep 9, 2021U
Completed
- Lymphoma, Non-Hodgkin's
- Obinutuzumab
- +3 more
- Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
2021-04-11
Apr 11, 2021M
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
- Houston, TexasM D Anderson Cancer Center
2021-11-18
Nov 18, 2021O
Completed
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ibrutinib
- Obinutuzumab
- Portland, OregonOHSU Knight Cancer Institute
2021-07-08
Jul 8, 2021S
Active, not recruiting
- Follicular Lymphoma
- Obinutuzumab
- Venetoclax
- Basel, Switzerland
- +5 more
2021-08-13
Aug 13, 2021D
Recruiting
- Graft vs. Host Disease
- Obinutuzumab
- Placebo
- Palo Alto, California
- +4 more
2021-06-25
Jun 25, 2021M
Terminated
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Lenalidomide
- Obinutuzumab
- Houston, TexasM D Anderson Cancer Center
2021-05-21
May 21, 2021N
Not yet recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2021-12-02
Dec 2, 2021D
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
- Stamford, Connecticut
- +4 more
2021-11-22
Nov 22, 2021P
Recruiting
- Follicular Lymphoma
- Obinutuzumab
- +2 more
- Houston, Texas
- +2 more
2020-11-30
Nov 30, 2020E
Not yet recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
- Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
2021-08-25
Aug 25, 2021M
Active, not recruiting
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
- Houston, TexasM D Anderson Cancer Center
2021-07-22
Jul 22, 2021A
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
- Boston, Massachusetts
- +1 more
2021-08-05
Aug 5, 2021G
Completed
- B-Cell Chronic Lymphocytic Leukemia
- B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
- Ibrutinib
- +2 more
- Huixquilucan, Estado De México, MexicoGrupo Cooperativo de Hemopatías Malignas
2021-02-01
Feb 1, 2021S
Terminated
- Lymphocytic Leukemia, Chronic
- Lymphoma, Small Lymphocytic
- IPI-145 (duvelisib)
- Obinutuzumab
- La Jolla, California
- +6 more
2021-03-15
Mar 15, 2021A
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- acalabrutinib
- +3 more
- Columbus, OhioResearch Site
2021-09-14
Sep 14, 2021H
Recruiting
- Lymphoma, Non-Hodgkin
- RO7227166
- +3 more
- Melbourne, Victoria, Australia
- +11 more
2021-11-10
Nov 10, 2021